Advanced search
1 file | 3.99 MB Add to list

A comprehensive view of N-glycosylation as clinical biomarker in prostate cancer

Lissa Eggermont (UGent) , Nicolaas Lumen (UGent) , Charles Van Praet (UGent) , Joris Delanghe (UGent) , Sylvie Rottey (UGent) and Tijl Vermassen (UGent)
Author
Organization
Abstract
Alterations in the prostate cancer (PCa) N-glycome have gained attention as a potential biomarker. This comprehensive review explores the diversity of N-glycosylation patterns observed in PCa-related cell lines, tissue, serum and urine, focusing on prostate-specific antigen (PSA) and the total pool of glycoproteins. Within the context of PCa, altered N-glycosylation patterns are a mechanism of immune escape and a disruption in normal glycoprotein distribution and trafficking. Glycoproteins with PCa-induced N-glycosylation patterns tend to accumulate in prostate tissue and the bloodstream, thereby diminishing N-glycan proportions in urine. Based on literary observations, aberrations in N-glycan branching are probably a characteristic of metabolic reprogramming and (chronic) inflammation. Changes in (core) fucosylation, specific N-glycosylation structures (such as N, N '-diacetyllactosamine) and high-mannose glycans otherwise are more likely indicators of cancer development and progression. Further investigation into these PCa-specific alterations holds promise in the discovery of new diagnostic, prognostic and response prediction biomarkers in PCa.
Keywords
Prostate cancer, N-linked glycosylation, Biomarker, Diagnosis, Prognosis, ABERRANT GLYCOSYLATION, ALTERED GLYCOSYLATION, POTENTIAL BIOMARKERS, PSA GLYCOSYLATION, LINKED GLYCANS, ANTIGEN PSA, DIAGNOSIS, LECTIN, SIALYLATION, SPECIFICITY

Downloads

  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 3.99 MB

Citation

Please use this url to cite or link to this publication:

MLA
Eggermont, Lissa, et al. “A Comprehensive View of N-Glycosylation as Clinical Biomarker in Prostate Cancer.” BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, vol. 1880, no. 1, 2025, doi:10.1016/j.bbcan.2024.189239.
APA
Eggermont, L., Lumen, N., Van Praet, C., Delanghe, J., Rottey, S., & Vermassen, T. (2025). A comprehensive view of N-glycosylation as clinical biomarker in prostate cancer. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1880(1). https://doi.org/10.1016/j.bbcan.2024.189239
Chicago author-date
Eggermont, Lissa, Nicolaas Lumen, Charles Van Praet, Joris Delanghe, Sylvie Rottey, and Tijl Vermassen. 2025. “A Comprehensive View of N-Glycosylation as Clinical Biomarker in Prostate Cancer.” BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER 1880 (1). https://doi.org/10.1016/j.bbcan.2024.189239.
Chicago author-date (all authors)
Eggermont, Lissa, Nicolaas Lumen, Charles Van Praet, Joris Delanghe, Sylvie Rottey, and Tijl Vermassen. 2025. “A Comprehensive View of N-Glycosylation as Clinical Biomarker in Prostate Cancer.” BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER 1880 (1). doi:10.1016/j.bbcan.2024.189239.
Vancouver
1.
Eggermont L, Lumen N, Van Praet C, Delanghe J, Rottey S, Vermassen T. A comprehensive view of N-glycosylation as clinical biomarker in prostate cancer. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER. 2025;1880(1).
IEEE
[1]
L. Eggermont, N. Lumen, C. Van Praet, J. Delanghe, S. Rottey, and T. Vermassen, “A comprehensive view of N-glycosylation as clinical biomarker in prostate cancer,” BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, vol. 1880, no. 1, 2025.
@article{01JQNPTCN6E50BGWQ1ACYJQXPY,
  abstract     = {{Alterations in the prostate cancer (PCa) N-glycome have gained attention as a potential biomarker. This comprehensive review explores the diversity of N-glycosylation patterns observed in PCa-related cell lines, tissue, serum and urine, focusing on prostate-specific antigen (PSA) and the total pool of glycoproteins. Within the context of PCa, altered N-glycosylation patterns are a mechanism of immune escape and a disruption in normal glycoprotein distribution and trafficking. Glycoproteins with PCa-induced N-glycosylation patterns tend to accumulate in prostate tissue and the bloodstream, thereby diminishing N-glycan proportions in urine. Based on literary observations, aberrations in N-glycan branching are probably a characteristic of metabolic reprogramming and (chronic) inflammation. Changes in (core) fucosylation, specific N-glycosylation structures (such as N, N '-diacetyllactosamine) and high-mannose glycans otherwise are more likely indicators of cancer development and progression. Further investigation into these PCa-specific alterations holds promise in the discovery of new diagnostic, prognostic and response prediction biomarkers in PCa.}},
  articleno    = {{189239}},
  author       = {{Eggermont, Lissa and Lumen, Nicolaas and Van Praet, Charles and Delanghe, Joris and Rottey, Sylvie and Vermassen, Tijl}},
  issn         = {{0304-419X}},
  journal      = {{BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER}},
  keywords     = {{Prostate cancer,N-linked glycosylation,Biomarker,Diagnosis,Prognosis,ABERRANT GLYCOSYLATION,ALTERED GLYCOSYLATION,POTENTIAL BIOMARKERS,PSA GLYCOSYLATION,LINKED GLYCANS,ANTIGEN PSA,DIAGNOSIS,LECTIN,SIALYLATION,SPECIFICITY}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{15}},
  title        = {{A comprehensive view of N-glycosylation as clinical biomarker in prostate cancer}},
  url          = {{http://doi.org/10.1016/j.bbcan.2024.189239}},
  volume       = {{1880}},
  year         = {{2025}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: